Pneumology - Reviews
Early Access
Inflammation markers in lung cancer: prognostic and predictive value
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 23 October 2025
680
Views
241
Downloads
Authors
Lung cancer is a complex and heterogeneous disease with significant morbidity and mortality worldwide. Over the years, several inflammation markers have been studied, such as molecules, cells, genes, etc., that are implicated in the extremely complex interactions taking place in the inflammatory process implicated in cancer development. This narrative review aims to present the most commonly studied inflammation markers in lung cancer, including C-reactive protein, tumor necrosis factor family members, and prostaglandin E synthase enzyme 3, as well as the significant number of scores and indexes that have been developed to improve the prognostic and predictive potential for non-small cell lung cancer and small cell lung cancer patients of different stages and treatment approaches. Scores and indexes originating from a combination of variables used in everyday clinical practice are emphasized due to their simplicity and cost-effectiveness. Studies addressing the prognostic and predictive value of the most important and recently studied markers, indexes, and scores in lung cancer are summarized, revealing their potential as indicators of overall survival, therapeutic response, and tumor immune characteristics. Limitations in utilizing inflammation markers as predictive biomarkers are discussed, including assay standardization, the complexity of the inflammatory response, confounding factors, and the dynamic nature of marker assessment. The progress of biotechnology, along with the combination of routine clinical practice insights, could result in the development of inflammation markers with improved prognostic and predictive value guiding treatment decisions for lung cancer patients in the context of precision medicine.
Downloads
Download data is not yet available.
Citations
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63. DOI: https://doi.org/10.3322/caac.21834
Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 2023;20:624-39. DOI: https://doi.org/10.1038/s41571-023-00798-3
Wang Q, Gümüş ZH, Colarossi C, et al. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol 2023;18:31-46. DOI: https://doi.org/10.1016/j.jtho.2022.10.002
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. DOI: https://doi.org/10.1016/j.cell.2011.02.013
Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:263. DOI: https://doi.org/10.1038/s41392-021-00658-5
Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014;15:e493-503. DOI: https://doi.org/10.1016/S1470-2045(14)70263-3
Tan Z, Xue H, Sun Y, et al. The role of tumor inflammatory microenvironment in lung cancer. Front Pharmacol 2021;12:688625. DOI: https://doi.org/10.3389/fphar.2021.688625
Jin K, Qian C, Lin J, Liu B. Cyclooxygenase-2-prostaglandin E2 pathway: a key player in tumor-associated immune cells. Front Oncol 2023;13:1099811. DOI: https://doi.org/10.3389/fonc.2023.1099811
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev 2020;86:102019. DOI: https://doi.org/10.1016/j.ctrv.2020.102019
Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B. Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients. BMC Cancer 2022;22:63. DOI: https://doi.org/10.1186/s12885-021-09108-5
Gao P, Zou K, Xiao L, et al. High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Int Immunopharmacol 2022;110:108954. DOI: https://doi.org/10.1016/j.intimp.2022.108954
Shao F, Mao H, Luo T, et al. HPGDS is a novel prognostic marker associated with lipid metabolism and aggressiveness in lung adenocarcinoma. Front Oncol 2022;12:894485. DOI: https://doi.org/10.3389/fonc.2022.894485
Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α (TNF-α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med 2021;10:12759-66. DOI: https://doi.org/10.21037/apm-21-3471
Huang H, Yu H, Li X, et al. Genomic analysis of TNF-related genes with prognosis and characterization of the tumor immune microenvironment in lung adenocarcinoma. Front Immunol 2022;13:993890. DOI: https://doi.org/10.3389/fimmu.2022.993890
Wang T, Luo Y, Zhang Q, et al. COX-2-related tumor immune microenvironment in non-small cell lung cancer: a novel signature to predict hot and cold tumor. J Thorac Dis 2022;14:729-40. DOI: https://doi.org/10.21037/jtd-22-257
Liu CH, Di YP. Matrix metallopeptidase-gene signature predicts stage I lung adenocarcinoma survival outcomes. Int J Mol Sci 2023;24:2382. DOI: https://doi.org/10.3390/ijms24032382
Hu Y, Li S, Xiao H, et al. Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer. Cancer Med 2023;12:12234-52. DOI: https://doi.org/10.1002/cam4.5918
Kim HJ, Jo MJ, Kim BR, et al. Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. OncoTargets Ther 2018;11:4233-46. DOI: https://doi.org/10.2147/OTT.S161587
Xiao X, Wang S, Long G. C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer. Medicine 2019;98:e16238. DOI: https://doi.org/10.1097/MD.0000000000016238
Kuusisalo S, Tikkanen A, Lappi‐Blanco E, et al. The prognostic and predictive roles of plasma C‐reactive protein and PD‐L1 in non‐small cell lung cancer. Cancer Med 2023;12:16087-97. DOI: https://doi.org/10.1002/cam4.6262
Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J 2012;53:111-7. DOI: https://doi.org/10.3349/ymj.2012.53.1.111
Kajikawa S, Ohashi W, Kato Y, et al. Prognostic impact of serum procalcitonin in non-small cell lung cancer. Tumori 2021;107:385-91. DOI: https://doi.org/10.1177/0300891620966647
Ichikawa K, Watanabe S, Miura S, et al. Prognostic significance of procalcitonin in small cell lung cancer. Transl Lung Cancer Res 2022;11:43-52. DOI: https://doi.org/10.21037/tlcr-21-838
Banna GL, Friedlaender A, Tagliamento M, et al. Biological rationale for peripheral blood cell–derived inflammatory indices and related prognostic scores in patients with advanced non-small-cell lung cancer. Curr Oncol Rep 2022;24:1851-62. DOI: https://doi.org/10.1007/s11912-022-01335-8
Sandfeld-Paulsen B, Meldgaard P, Sorensen BS, et al. The prognostic role of inflammation-scores on overall survival in lung cancer patients. Acta Oncol 2019;58:371-6. DOI: https://doi.org/10.1080/0284186X.2018.1546057
Shen YJ, Qian LQ, Ding ZP, et al. Prognostic value of inflammatory biomarkers in patients with stage I lung adenocarcinoma treated with surgical dissection. Front Oncol 2021;11:711206. DOI: https://doi.org/10.3389/fonc.2021.711206
Zhang CL, Gao MQ, Jiang XC, et al. Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence. Ann Med 2023;55:1294-307. DOI: https://doi.org/10.1080/07853890.2023.2192047
Kauffmann-Guerrero D, Kahnert K, Kiefl R, et al. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study. Sci Rep 2021;11:10919. DOI: https://doi.org/10.1038/s41598-021-90397-y
Li C, Wu J, Jiang L, et al. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. Cancer Immunol Immunother 2023;72:783-94. Erratum in: Cancer Immunol Immunother 2023;72:795. DOI: https://doi.org/10.1007/s00262-022-03294-2
Xie H, Ruan G, Wei L, et al. The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non‐small cell lung cancer. J Cachexia Sarcopenia Muscle 2023;14:869-78. DOI: https://doi.org/10.1002/jcsm.13199
Mahiat C, Bihin B, Duplaquet F, et al. Systemic inflammation/nutritional status scores are prognostic but not predictive in metastatic non-small-cell lung cancer treated with first-line immune checkpoint inhibitors. Int J Mol Sci 2023;24:3618. DOI: https://doi.org/10.3390/ijms24043618
Mountzios G, Samantas E, Senghas K, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open 2021;6:100254. DOI: https://doi.org/10.1016/j.esmoop.2021.100254
Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B. Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis. Syst Rev 2021;10:40. DOI: https://doi.org/10.1186/s13643-021-01585-w
Chen C, Yang H, Cai D, et al. Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res 2021;10:866-77. DOI: https://doi.org/10.21037/tlcr-20-997
Zhou T, Zhao Y, Zhao S, et al. Comparison of the prognostic value of systemic inflammation response markers in small cell lung cancer patients. J Cancer 2019;10:1685-92. DOI: https://doi.org/10.7150/jca.29319
Liu C, Jin B, Liu Y, et al. Construction of the prognostic model for small‐cell lung cancer based on inflammatory markers: a real‐world study of 612 cases with eastern cooperative oncology group performance score 0–1. Cancer Med 2023;12:9527-40. DOI: https://doi.org/10.1002/cam4.5728
Qi WX, Xiang Y, Zhao S, Chen J. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother 2021;70:3199-206. DOI: https://doi.org/10.1007/s00262-021-02926-3
Yilmaz H, Yersal Ö. Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer. J Cancer Res Ther 2022;18:691-6. DOI: https://doi.org/10.4103/jcrt.jcrt_1937_21
Kutlu Y, Aydin SG, Bilici A, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy. Medicine 2023;102:e33432. DOI: https://doi.org/10.1097/MD.0000000000033432
Gong Y, Pang H, Yu Z, et al. Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity. Ann Med 2023;55:2200034. DOI: https://doi.org/10.1080/07853890.2023.2200034
Ansar W, Ghosh S. Inflammation and inflammatory diseases, markers, and mediators: role of CRP in some inflammatory diseases. Biology of C Reactive Protein in Health and Disease 2016:67-107. DOI: https://doi.org/10.1007/978-81-322-2680-2_4
Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of inflammation. In: DeWitt JC, Rockwell CE, Bowman CC, eds. Immunotoxicity testing. New York, NY, USA: Springer New York; 2018. pp. 57-79. Cocoş R, Mahler B, Turcu-Stiolica A, et al. Risk of death in comorbidity subgroups of hospitalized covid-19 patients inferred by routine laboratory markers of systemic inflammation on admission: a retrospective study. Viruses 2022;14:1201. DOI: https://doi.org/10.3390/v14061201
Luo L, Tan Y, Zhao S, et al. The potential of high-order features of routine blood test in predicting the prognosis of non-small cell lung cancer. BMC Cancer 2023;23:496. DOI: https://doi.org/10.1186/s12885-023-10990-4
How to Cite
“Inflammation Markers in Lung Cancer: Prognostic and Predictive Value”. 2025. Monaldi Archives for Chest Disease, October. https://doi.org/10.4081/monaldi.2025.3580.
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.